Novus Biologicals products are now on bio-techne.com

Recombinant Human CXCL9/MIG Protein

Images

 
There are currently no images for CXCL9/MIG (392-MG).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human CXCL9/MIG Protein Summary

Details of Functionality
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with mouse CXCR3. The ED50 for this effect is 0.1‑0.4 µg/mL.
Source
E. coli-derived human CXCL9/MIG protein
Thr23-Thr125
Accession #
N-terminal Sequence
Thr23
Protein/Peptide Type
Recombinant Proteins
Gene
CXCL9
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity
Theoretical MW
11.7 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Publications
Read Publications using
392-MG in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CXCL9/MIG Protein

  • chemokine (C-X-C motif) ligand 9
  • CMK
  • crg-10
  • C-X-C motif chemokine 9
  • CXCL9
  • Gamma-interferon-induced monokine
  • Humig
  • MIG
  • MIGSmall-inducible cytokine B9
  • monokine induced by gamma interferon
  • SCYB9Monokine induced by interferon-gamma

Background

CXCL9, a member of the alpha  subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. Human CXCL9 was subsequently cloned using mouse MIG cDNA as a probe. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-gamma . CXCL9 has been shown to be a chemoattractant for activated T‑lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid residue precursor protein with a 22 amino acid residue signal peptide that is cleaved to yield a 103 amino acid residue mature protein. CXCL9 has an extended carboxy‑terminus containing greater than 50% basic amino acid residues and is larger than most other chemokines. The carboxy‑terminal residues of CXCL9 are prone to proteolytic cleavage resulting in size heterogeneity of natural and recombinant CXCL9. CXCL9 with large carboxy‑terminal deletions have been shown to have diminished activity in the calcium flux assay. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has been cloned and shown to be highly expressed in IL-2-activated T‑lymphocytes. The E. coli‑expressed CXCL9 preparations produced at R&D Systems have been shown to contain greater than 80% full length CXCL9.

  1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
  2. Liao, F. et al. (1995) J. Exp. Med. 182:1301.
  3. Vanguri, P. (1995) J. Neuroimmunol. 56:35.

Customers Who Viewed This Item Also Viewed...

DIP100
Species: Hu
Applications: ELISA
DCX110
Species: Hu
Applications: ELISA
MAB160
Species: Hu
Applications: CyTOF-ready, Flow, IHC, Neut
DCP00
Species: Hu
Applications: ELISA
DRN00B
Species: Hu
Applications: ELISA
MAB208
Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, ICFlow, Neut, Simple Western, WB
M6000B
Species: Mu
Applications: ELISA
DY417
Species: Mu
Applications: ELISA
6507-IL/CF
Species: Hu
Applications: BA
NBP1-19371
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
MCC170
Species: Mu
Applications: ELISA
MME00
Species: Mu
Applications: ELISA
NBP1-49045
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
DMD00
Species: Hu
Applications: ELISA
MMA00
Species: Mu
Applications: ELISA
202-IL
Species: Hu
Applications: BA
DY453
Species: Mu
Applications: ELISA
MAB182
Species: Hu
Applications: CyTOF-ready, Flow, ICC, Neut

Publications for CXCL9/MIG (392-MG)(13)

We have publications tested in 3 confirmed species: Human, N/A, Virus.

We have publications tested in 3 applications: Binding Assay, Bioassay, ELISA (Standard).


Filter By Application
Binding Assay
(1)
Bioassay
(9)
ELISA (Standard)
(4)
All Applications
Filter By Species
Human
(8)
N/A
(1)
Virus
(1)
All Species
Showing Publications 1 - 10 of 13. Show All 13 Publications.
Publications using 392-MG Applications Species
ST Kim, Y Chu, M Misoi, ME Suarez-Alm, JH Tayar, H Lu, M Buni, J Kramer, E Rodriguez, Z Hussain, SS Neelapu, J Wang, AY Shah, NM Tannir, MT Campbell, DL Gibbons, T Cascone, C Lu, GR Blumensche, M Altan, B Lim, V Valero, ME Loghin, J Tu, SN Westin, A Naing, G Garcia-Man, N Abdel-Waha, HA Tawbi, P Hwu, ICG Oliva, MA Davies, SP Patel, J Zou, A Futreal, A Diab, L Wang, R Nurieva Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy Nature Communications, 2022-04-12;13(1):1970. 2022-04-12 [PMID: 35413951] (Bioassay, Human) Bioassay Human
M Goedhart, S Gessel, R van der Vo, E Slot, B Lucas, E Gielen, M Hoogenboez, T Rademakers, S Geerman, JD van Buul, S Huveneers, H Dolstra, G Anderson, C Voermans, MA Nolte CXCR4, but not CXCR3, drives CD8 T-cell entry into and migration through the murine bone marrow Eur. J. Immunol., 2019-02-15;0(0):. 2019-02-15 [PMID: 30707456] (Bioassay, Human) Bioassay Human
H Bronger, A Karge, T Dreyer, D Zech, S Kraeft, S Avril, M Kiechle, M Schmitt Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells Oncol Lett, 2017-04-05;13(6):4224-4230. 2017-04-05 [PMID: 28599423] (Bioassay, Human) Bioassay Human
Sugita S, Kamao H, Iwasaki Y, Okamoto S, Hashiguchi T, Iseki K, Hayashi N, Mandai M, Takahashi M Inhibition of T-cell activation by retinal pigment epithelial cells derived from induced pluripotent stem cells. Invest Ophthalmol Vis Sci, 2015-01-20;56(2):1051-62. 2015-01-20 [PMID: 25604685] (Bioassay, Human) Bioassay Human
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human) Bioassay Human
Badr G, Lefevre EA, Mohany M Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS ONE, 2011-09-01;6(9):e23741. 2011-09-01 [PMID: 21912642] (Bioassay, Human) Bioassay Human
Liu C, Luo D, Reynolds BA Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis, 2010-11-03;32(2):129-37. 2010-11-03 [PMID: 21051441] (Bioassay, Human) Bioassay Human
Biancotto A, Iglehart SJ, Lisco A, Vanpouille C, Grivel JC, Lurain NS, Reichelderfer PS, Margolis LB Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo. AIDS Res. Hum. Retroviruses, 2008-03-01;24(3):453-62. 2008-03-01 [PMID: 18327985] (ELISA (Standard)) ELISA (Standard)
Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS, 2007;21(10):1263-72. 2007 [PMID: 17545702] (ELISA (Standard), N/A) ELISA (Standard) N/A
Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, Debernardo R, Garate K, Rodriguez B, Margolis LB, Lederman MM Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood, 2007-02-08;109(10):4272-9. 2007-02-08 [PMID: 17289812] (ELISA (Standard)) ELISA (Standard)
Show All 13 Publications.

Reviews for CXCL9/MIG (392-MG) (0)

There are no reviews for CXCL9/MIG (392-MG). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for CXCL9/MIG (392-MG) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional CXCL9/MIG Products

Blogs on CXCL9/MIG

There are no specific blogs for CXCL9/MIG, but you can read our latest blog posts.
Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human CXCL9/MIG Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol CXCL9
Uniprot